|Publication number||US3659600 A|
|Publication date||May 2, 1972|
|Filing date||Feb 24, 1970|
|Priority date||Feb 24, 1970|
|Publication number||US 3659600 A, US 3659600A, US-A-3659600, US3659600 A, US3659600A|
|Inventors||Merrill Edward W|
|Original Assignee||Charles River Foundation The, Estin Hans H, Leonard W Cronkhite Jr, William W Wolbach|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (6), Referenced by (97), Classifications (7), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
I United States Patent 1 1 3,659,600 Merrill [451 May 2, 1972 54] MAGNETICALLY OPERATED CAPSULE 3,485,235 12 1969 Fetson ..12s 2 R FOR ADMINISTERING DRUGS 3,118,439 1/1964 Perrenoud... ..128/2 R 3,419,008 12/1968 Plishnerl... .....128/1 R X  Invent": Edwm cambndge' Mass- 3,093,831 6/1963 Jordan ..l28/260 x  Assignee: Hans H. Estin, Leonard W. Cronkhite, Jr.
and William W. Wolbach, Trustees of the Primary Examiner-Richard A. Gaudet Charles River Foundation, Boston, Mass. Assistant Examiner-J. B. Mitchell  Filed: 24, 1970 Attorney-Kenway, Jenney & lelildreth  Appl. No.: 13,278 57 ABST CT An implantable capsule for delivering drugs when subjected to  [1.5-
a magnetic force outside the and ontrolled the pa. ll!!- Cl- ..A6lm tient The ca ule has a means movable under a magnetic  held Search "128/1721 force to effect contact of the medicament in the capsule with a 128/11 2 P drug-permeable wall. When contacted, the drug diffuses through the wall into the body. When it is desired to cease  References Cited drug administration, the capsule is subjected to an opposite UNITED STATES PATENTS magnetic force to seal the permeable wall from contact with the drug. 3,315,660 4/1967 Abella ..128/2 R Long, Jr. et a1. ..128/272 X 3 Claims, 2 Drawing Figures Patented May 2, 1972 3,659,600
INVENTOR EDWARD W. MERRILL- r $1M 7? ATTORNEYS MAGNETICALLY OPERATED CAPSULE FOR ADMINISTERING DRUGS This invention relates to a capsule activated by magnetic force to release a medicament.
Capsules implanted into the human body to administer long-acting drugs such as regulatory hormones over long periods have in general been simple passive systems. The drug diffuses from the capsule interior through the capsule walls into the body at a rate governed exclusively by the wall thickness and the concentration of the drug. No independent control is imposed either by the exterior chemical milieu of the patient or by any action on the part of the patient, to regulate the rate of drug diffusion or when administration is initiated and ceased. Since the patient either does not have a continuous need for the drug but usually has a need governed by a convenient schedule or when physiological sensation informs him of the need for the drug, it would be highly desirable to provide a drug-filled capsule implanted into the patient for the purpose of administering the drug on a non-continuous basis and/or on any convenient schedule desired by the patient through the use of means solely within his control.
The present invention provides capsules suitable for implantation into the body for administering a drug from the interior of the implanted capsule to the body by subjecting the capsule to magnetic force from a source located outside of the body. When the magnetic force is applied from one direction, a magnetic means within the capsule is caused to move thereby effecting delivery of a quantity of a drug from a storage compartment in the capsule from which it diffuses through a permeable wall portion of the capsule into living tissue.
Only a portion of the capsule wall need be constructed of a material permeable to a drug contained in the capsule while the remainder of the capsule wall is non-permeable to the drug. A magnetically activatable means in the capsule is adapted to move within the capsule either linearly or rotationally under a magnetic force to provide or terminate contact of the drug-permeable wall portion and the drug in the capsule as desired. When the drug and permeable wall are brought into contact, the drug begins to difi'use into the permeable wall and thence, subsequently, into the body. When the drug and permeable wall are removed from contact, the permeable wall releases drugs already in it, at an ever decreasing rate, and finally is exhausted of drug. Administration of the drug can be controlled easily by the patient by positioning the source of the magnetic force outside the body to move the magnetically activatable means and provide or terminate contact of the drug and permeable wall for the period desired by the patient.
The process of this invention for administering drugs, and the capsule therefor provide substantial advantages over presently available means for administering drugs from an implanted capsule, in that administration is within theexclusive control of the patient. Furthermore, the present invention permits the administration of drugs from implanted capsules which drugs were previously administered by other means due to the need for non-continuous administration.
FIG. 1 is a sectional view of a cylindrical capsule of this invention especially suited for contraceptive drugs such as progestin, taken along the midplane coextensive with its major axis showing the magnetically operable means in two posi tions.
FIG. 2 is a sectional bottom view of a capsule of FIG. 1 taken along line 2-2 and provided with additional structural supports.
Referring to FIG. 1 the retaining capsule 1 having a cylindrical shape is defined by ends 2 and 3, non-permeable cylindrical wall 4 and permeable wall 5 supported on screen 6 to provide mechanical strength. The retaining capsule 1 contains a magnetic hollow piston 7, a spring 8 and either a drug solution or the drug itself. The spring 8, drug and piston 7 can be inserted into the capsule 1 by removing cap 3 and thereafter sealing the cap 3 in place. The spring 8, has a low spring constant which maintains the piston 7 against the end 2 in the rest state. When the capsule is subjected to a magnetic force from a source outside the body, the piston 7 is moved to a position 8 shown by the dotted lines. The piston movement compresses the spring 8, and, because piston 7 is hollow, the contained drug, drug solution, or drug suspension moves through the piston 7 and contacts permeable wall 5. The drug diffuses through the wall 5 at a diffusion rate controlled by the thickness of wall 5 and the concentration of the drug. The rate of administration of the drug is controlled by the surface area of wall 5 and the drug diffusion rate. When it is desired to stop drug administration, as for example, to turn off a contraceptive hormone in order to permit conception, the patient reverses the process, and magnetically attracts the piston 7 to position A which movement is assisted by spring 8. When the piston is in position A, the walls is effectively sealed from contact with the drug. Spring 8 maintains piston 7 in a fail-safe position; that is to say, unless a magnet force is intentionally applied to move piston 7, the neutral position of piston 7 is to seal the wall 5 from contact with the drug.
Referring to FIG. 2, the capsule of FIG. 1 is modified to include supports 10 extending between the end piece 2 and the wall 4 to provide a rigid support for membranes 5. The interior surface 11 of the supports 10 conform to that of the interior surfaces of end piece 2 and wall 4 to permit smooth and undisturbed movement of piston 7 and also to reduce the possibility of damaging wall 5. Any number of supports 10 can be used with 3, 4 or 6 being preferred.
The end pieces and rigid wall of the capsule are constructed of materials which are non-magnetic, and non-toxic, do not degrade the drug, have long durability in contact with body fluids and negligible permeability. Furthermore, any material used in the formation of the capsule must have the fundamental properties of high mechanical-strength against fracture by accidental blows. Suitable materials for use in the capsule are non-magnetic metals such as tantalum, non-magnetic stainless steels, platinum, or the like or non-metals such as polycarbonates or the like. The free moving piston 7 must be of ferromagnetic materials, and in general it must be coated to prevent its corrosion in or contamination of the contained drug or drug solution. The piston can be coated with ceramic enamels by high temperature fusion, organic enamels of high strength and abrasion resistance such as phenol-formaldehyde resin, or the like.
The permeable membrane is preferably made of a crosslinked elastomer or a network polymer in a swollen solvated state which is highly permeable to the drug. Generally speaking, polymers in their glassy state are not desirable for this purpose, because of their inordinately low permeability,-but cellulose acetate Loef type reverse osmosis membranes, suitably modified to increase pore size, may be used. The elastomeric material employed to form the permeable wall must be nontoxic, cross-linkable to the desired elastic modulus, inert to the drug and have a finite permeability to the contained drug to give accurate slow release of the drug into the body upon implantation. Non-toxic additives, usually employed in the elastomeric materials, may be employed include fillers such as silica or the like, provided only that the capsule retains its final shape after its processingand the drug can be diffused through the elastomer. For a lipid soluble medicament or drug, including steroid hormones such as the progestins, and estrogen, it is preferred to employ silicone rubbers i.e., organopolysiloxane wherein the organic groups attached is the silicon atom preferably methyl, phenyl, vinyl, or combinations thereof. This preference is because silicone rubbers have relative freedom from toxic products of vulcanization, and are inert as an implanted material.
In general, the permeable wall of the cylindrical capsule can beformed by compression moldingand vulcanization, or by an equivalent procedure so that'the wall material is crosslinked'while being contained between mating interior and exterior molds to produce a product having a smooth continuous surface co-extensive with the interior surface of the capsule. Cross-linkingcan-be efl'ected in any manner well known in the art, including ionizing radiation which is especially appropriate to silicone elastomers. After cross-linking, the permeable wall is treated to remove by-products of the crosslinking step, if any, which may be toxic or which may degrade the drug. Thus, for example, phenyl benzoate produced by thermal decomposition of benzoyl peroxide initiator can be removed by extraction. The membrane is bonded to the wall of the capsule in any convenient manner. Thus, the membrane can be molded and cross-linked while in contact with the nonpermeable capsule wall to thereby provide an effective seal. The surface of the wall also can be modified or coated with a material to effect a strong seal with the membrane. Thereafter, the decomposition products from the crosslinking step can be removed from the membrane prior to filling the capsule.
Once the cylindrical capsule has been filled with the drug,
the sliding piston and the retaining spring, it is convenient to seal the end plate 3 by some relatively permanent means, such as with a permanent non-toxic adhesives such as epoxy or by heat sealing the material if it be polymeric, such as a polycarbonate or the like.
It is essential that the sliding piston move freely but snugly within the capsule to provide efi'ective sealing or contact of the penneable wall and drug. The piston material or coating used on the piston shouldnot adhere to any of the surfaces with which it contacts and there must be geometric precision between the sliding piston and the interior surface of the capsule. The length of the sliding piston is significantly greater than the corresponding length of the permeable wall, so that when it is in the closed position leakage of the drug is minimized. Generally, the capsule is 4 to 15mm. long and 2 to mm. wide the piston being about 2.5mm. to 10mm. long. It is desirable to minimize the piston wall thickness to maximize the amount of drug in the capsule. While the capsule of this invention is described with reference to a magnetically operable means comprising a hollow piston, it is to be understood that the magnetically operable means can be of any geometric shape so that it moves freely but snugly within the capsule to provide eflective sealing of the drug and permeable wall and permits contact of the drug and permeable wall when desired.
When the drug is a solid rather than a liquid it is desirable to form a solution thereof with a solvent or a dispersion thereof in an inert carrier liquid. The solvent employed should dissolve the drug to afford the preparation of concentrated solution, and must be inert to both the drug and the elastomeric material. A suitable carrier liquid should be inert to the drug, and capable of suspending the drug when the drug is rendered into microparticles. Thus, ideally the carrier liquid has the same density as the drug. Accordingly, the choice of solvent and elastomer is made depending upon the drug used to fill the capsule.
The particular elastomer and solvent employed for a given drug are chosen in accordance with the criteria set forth above for the drug-solvent-elastomer system. Commonly employed solvents and carrier liquids useful in the present invention include glycols, such as propylene glycol; glycerol; selected animal fats; hydrogenated vegetable oils; mineral oil; silicone oils and mixtures thereof. Silicone oils include not only the common homopolymers poly [dimethyl siloxane], but also the homopolymers poly [diphenyl siloxane], poly [methyl phenyl siloxane], poly [methy], B-carboxyethyl siloxane and random copolymers and interpolymers based on the mer units of the above stated homopolymers. Colloidal silica may conveniently be used as a thickening agent to maintain dispersion of suspended drug, above or in combination with polymeric additives to assist in maintaing dispersion.
The following example illustrates the present invention and is not intended to limit the same.
EXAMPLE I A cylindrical capsule of the form shown in FIG. 1 having an internal diameter of 0.600 cm. and an internal length of [.2 cm. is formed by IIIJCCDOI'I molding from polycarbonate, with six supporting pillars, (10 in FIG. 2) equally spaced, being used as a frame on which a silicone membrane is subsequently cast. Stainless wire (20mil. diameter) is spirally wound over the six pillars so as to form a support for the silicone composition. Ends of the wire are seized by forcing them into holes drilled in the polycarbonate body above and below the membrane area, then heat sealing.
The total height of the pillars defining the membrane area is 0.40cm. A dummy plug is driven into the capsule so as to form an internal mold surface, and silicone RTV rubber of the acetoxy type is forced through the stainless steel wire and around the posts until it fills the space bonded by the dummy plug. A cellophane tape is applied externally by means of a dental clamp to support the liquid silicone, and air cure is allowed to occur for 24 hours, followed by immersion in C., water for 1 hour to extract residual acetic acid and complete hydrolysis of the silicone rubber now solidified as a membrane around the stainless steel wire, the polycarbonate posts and the upper and lower portions of the polycarbonate body.
The dummy is removed and the capsule is filled through its open end 3 (FIG. 1) with a suspension of 25 parts estrogen hormone in 75 parts dimethyl silicone oil of viscosity 1,000 centipose, thickened by part of Cubosil(TM) silica. A hollow cylinder formed of soft magnetic iron, machined and then coated with a ceramic tocover all areas, having a length of 0.60cm., an inside diameter of 0.35cm., and an outside diameter of 0.570cm. is inserted through the open end of the capsule and placed in the closed position but is over the membrane area. A tantalum spring exerting a force of 1.5 grams when fully collapsed, 0.6 grams when fully extended, is placed behind the hollow iron cylinder. A threaded end plate 3 is then screwed into the end of the capsule, eliminating all air from inside the capsule. Superficial heat sealing is used too at the external junction of the capsule body and the end plate to insure against leakage. The heat sealing is accomplished by a rapid use of a miniature gas oxygen torch to effect superficial fusion without heating the main body of the capsule.
The capsule is designed for implantation in the upper thigh, at a depth of %cm., with the end 3 nearest the surface. A 40- gram AiNiCor rod magnet taped over the skin immediately above magnet is sufficient to keep the internal hollow iron cylinder in the open position, for release of the contraceptive estrogen. Removal of the magnet allows immediate close of the membrane area from access of the estrogen-silicone oil suspension, and within 8 hours the rate of release of estrogen falls exponentially a value approximate by 5 percent of that corresponding to full open position (magnetic retraction of the hollow iron wire).
1. A capsule suitable for implantation in the human body which comprise a wall,
end sections attached to said wall to define a closed hollow chamber,
a medicament within said chamber,
a portion of said wall being formed of a permeable crosslinked elastomeric composition,
an open hollow magnet in said chamber being movable under a magnetic force to seal or expose the permeable wall portion to the medicament,
and a spring means in said chamber between said magnet and one of said end sections biasing said magnet toward a position to effect sealing of said permeable wall portion from said chamber.
2. The capsule of claim 1 wherein the permeable wall is formed of a cross-linked silicone rubber.
3. The capsule of claim 1 wherein the permeable wall portion is provided with a reinforcing means.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3093831 *||Oct 22, 1959||Jun 18, 1963||Jordan Gerhard Paul Wilhelm||Artificial gland|
|US3118439 *||Mar 19, 1958||Jan 21, 1964||Jean-Pierre Perrenoud||Diagnostic and medicating capsule and the method of use|
|US3279996 *||Aug 28, 1962||Oct 18, 1966||Folkman Moses Judah||Polysiloxane carrier for controlled release of drugs and other agents|
|US3315660 *||Aug 8, 1963||Apr 25, 1967||Abella Carlos A||Capsule for insertion in the digestive track|
|US3419008 *||Feb 24, 1966||Dec 31, 1968||Paul J. Plishner||Magnetically actuated valve clamp for urethra control|
|US3485235 *||Dec 4, 1967||Dec 23, 1969||Felson Ronald||Capsule for the study and treatment of the digestive tract|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3802425 *||Oct 14, 1971||Apr 9, 1974||Moulding T||Intrauterine contraceptive device|
|US3840009 *||Dec 27, 1971||Oct 8, 1974||Alza Corp||Self-powered vapor pressure delivery device|
|US3894538 *||Aug 6, 1973||Jul 15, 1975||Siemens Ag||Device for supplying medicines|
|US3903888 *||Mar 11, 1974||Sep 9, 1975||Minnesota Mining & Mfg||Time-delay metering dispenser|
|US3951147 *||Apr 7, 1975||Apr 20, 1976||Metal Bellows Company||Implantable infusate pump|
|US4005699 *||Oct 9, 1974||Feb 1, 1977||Louis Bucalo||Methods and apparatus for use in magnetic treatment of the body|
|US4197846 *||Jun 25, 1975||Apr 15, 1980||Louis Bucalo||Method for structure for situating in a living body agents for treating the body|
|US4265241 *||Feb 28, 1979||May 5, 1981||Andros Incorporated||Implantable infusion device|
|US4312347 *||Feb 25, 1980||Jan 26, 1982||Iowa State University Research Foundation, Inc.||Positive pressure drug releasing device|
|US4507115 *||Feb 28, 1984||Mar 26, 1985||Olympus Optical Co., Ltd.||Medical capsule device|
|US4541429 *||May 10, 1982||Sep 17, 1985||Prosl Frank R||Implantable magnetically-actuated valve|
|US5019372 *||Sep 7, 1990||May 28, 1991||The Children's Medical Center Corporation||Magnetically modulated polymeric drug release system|
|US5170801 *||Oct 2, 1990||Dec 15, 1992||Glaxo Inc.||Medical capsule device actuated by radio-frequency (rf) signal|
|US5217449 *||Dec 11, 1990||Jun 8, 1993||Miyarisan Kabushiki Kaisha||Medical capsule and apparatus for activating the same|
|US5279607 *||May 30, 1991||Jan 18, 1994||The State University Of New York||Telemetry capsule and process|
|US5395366 *||Jan 10, 1994||Mar 7, 1995||The State University Of New York||Sampling capsule and process|
|US6632216||Dec 20, 2000||Oct 14, 2003||Phaeton Research Ltd.||Ingestible device|
|US6939323 *||Jul 19, 2002||Sep 6, 2005||Massachusetts Institute Of Technology||Needleless injector|
|US7048730 *||Dec 22, 2003||May 23, 2006||Petrakis Dennis N||Temperature activated systems|
|US7066922||Oct 21, 2002||Jun 27, 2006||Massachusetts Institute Of Technology||Transdermal transport device with suction|
|US7160258||Jun 26, 2001||Jan 9, 2007||Entrack, Inc.||Capsule and method for treating or diagnosing the intestinal tract|
|US7282045||Jun 27, 2003||Oct 16, 2007||Phaeton Research Ltd.||Ingestible device|
|US7287485||May 19, 2006||Oct 30, 2007||Petrakis Dennis N||Temperature activated systems|
|US7364568||Oct 21, 2002||Apr 29, 2008||Massachusetts Institute Of Technology||Microneedle transdermal transport device|
|US7425204||Apr 28, 2005||Sep 16, 2008||Massachusetts Institute Of Technology||Needleless injector|
|US7429258||Sep 9, 2002||Sep 30, 2008||Massachusetts Institute Of Technology||Microneedle transport device|
|US7445616||Mar 17, 2004||Nov 4, 2008||Petrakis Dennis N||Temperature responsive systems|
|US7455668||Oct 30, 2007||Nov 25, 2008||Petrakis Dennis N||Temperature activated systems|
|US7476224||Apr 9, 2008||Jan 13, 2009||Petrakis Dennis N||Temperature responsive systems|
|US7497856 *||Aug 11, 2005||Mar 3, 2009||Fachhochschule Jena||Arrangement for remote-controlled release of active ingredients|
|US7530975||Sep 8, 2003||May 12, 2009||Massachusetts Institute Of Technology||Measuring properties of an anatomical body|
|US7607402||Oct 27, 2009||Petrakis Dennis N||Temperature responsive systems|
|US7645263||Oct 21, 2002||Jan 12, 2010||Massachusetts Institute Of Technology||Impedance sensor|
|US7651475||Jan 11, 2008||Jan 26, 2010||Massachusetts Institute Of Technology||Microneedle transport device|
|US7655001||Sep 29, 2008||Feb 2, 2010||Petrakis Dennis N||Temperature responsive systems|
|US7763014||Jul 30, 2007||Jul 27, 2010||Phaeton Research Ltd.||Ingestible device|
|US7824347||May 1, 2003||Nov 2, 2010||Entrack, Inc.||System for marking a location for treatment within the gastrointestinal tract|
|US8005536||Dec 22, 2003||Aug 23, 2011||Entrack, Inc.||Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract|
|US8048044 *||Nov 1, 2011||Stryker Corporation||Drug delivery system|
|US8061006 *||Jul 25, 2002||Nov 22, 2011||Powderject Research Limited||Particle cassette, method and kit therefor|
|US8105270||Jan 31, 2012||Massachusetts Institute Of Technology||Measuring properties of an anatomical body|
|US8172458||Sep 29, 2008||May 8, 2012||Petrakis Dennis N||Temperature responsive systems|
|US8246582||Aug 21, 2012||Massachusetts Institute Of Technology||Microneedle transdermal transport device|
|US8360976||Jan 29, 2013||Entrack, Inc.||Optical capsule and spectroscopic method for treating or diagnosing the intestinal tract|
|US8414559||May 7, 2009||Apr 9, 2013||Rainbow Medical Ltd.||Gastroretentive duodenal pill|
|US8517961||Nov 1, 2010||Aug 27, 2013||Entrack, Inc.||System for marking a location for treatment within the gastrointestinal tract|
|US8758271||Aug 31, 2010||Jun 24, 2014||Massachusetts Institute Of Technology||Nonlinear system identification techniques and devices for discovering dynamic and static tissue properties|
|US8915867||Aug 26, 2013||Dec 23, 2014||Entrack, Inc.||System for marking a location for treatment within the gastrointestinal tract|
|US9167990||Dec 23, 2013||Oct 27, 2015||Entrack, Inc.||Optical capsule and spectroscopic method for treating and diagnosing the intestinal tract|
|US9265461||Aug 31, 2010||Feb 23, 2016||Massachusetts Institute Of Technology||Identification techniques and device for testing the efficacy of beauty care products and cosmetics|
|US9308326||Sep 18, 2014||Apr 12, 2016||Massachusetts Institute Of Technology||Controlled needle-free transport|
|US9333060||Dec 15, 2010||May 10, 2016||Massachusetts Institute Of Technology||Plaque removal and differentiation of tooth and gum|
|US20020198470 *||Jun 26, 2001||Dec 26, 2002||Imran Mir A.||Capsule and method for treating or diagnosing the intestinal tract|
|US20030083611 *||Jul 19, 2002||May 1, 2003||Massachusetts Institute Of Technology||Needleless injector|
|US20030083618 *||Oct 21, 2002||May 1, 2003||Massachusetts Institute Of Technology||Transdermal transport device with an electrolytic actuator|
|US20030083641 *||Oct 21, 2002||May 1, 2003||Massachusetts Institute Of Technology||Impedance sensor|
|US20030083645 *||Sep 9, 2002||May 1, 2003||Massachusetts Institute Of Technology||Microneedle transport device|
|US20030139727 *||Oct 21, 2002||Jul 24, 2003||Massachusetts Institute Of Technology||Transdermal transport device with suction|
|US20040068204 *||May 1, 2003||Apr 8, 2004||Imran Mir A.||System for marking a location for treatment within the gastrointestinal tract|
|US20040106893 *||Sep 8, 2003||Jun 3, 2004||Massachusetts Institute Of Technology||Measuring properties of an anatomical body|
|US20040106894 *||Sep 8, 2003||Jun 3, 2004||Massachusetts Institute Of Technology||Needleless drug injection device|
|US20040134412 *||Dec 22, 2003||Jul 15, 2004||Petrakis Dennis N.||Temperature activated systems|
|US20040162469 *||Dec 22, 2003||Aug 19, 2004||Imran Mir A.||Optical capsule and spectroscopic method for treating or diagnosing the intestinal tract|
|US20040162501 *||Dec 22, 2003||Aug 19, 2004||Imran Mir A.||Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract|
|US20040253304 *||Jan 29, 2004||Dec 16, 2004||Yossi Gross||Active drug delivery in the gastrointestinal tract|
|US20040255447 *||Jul 25, 2002||Dec 23, 2004||Kendall Mark Anthony Fernance||Particle cassette, method and kit therefor|
|US20040267230 *||Aug 30, 2002||Dec 30, 2004||Felix Theeuwes||Flow regulator|
|US20040267240 *||May 3, 2004||Dec 30, 2004||Yossi Gross||Active drug delivery in the gastrointestinal tract|
|US20050058701 *||Jul 29, 2004||Mar 17, 2005||Yossi Gross||Active drug delivery in the gastrointestinal tract|
|US20050256448 *||Apr 28, 2005||Nov 17, 2005||Massachusetts Institute Of Technology||Needleless injector|
|US20060015088 *||Aug 11, 2005||Jan 19, 2006||Fachhochschule Jena||Arrangement for remote-controlled release of active ingredients|
|US20060207495 *||May 19, 2006||Sep 21, 2006||Petrakis Dennis N||Temperature activated systems|
|US20060260534 *||Mar 17, 2004||Nov 23, 2006||Petrakis Dennis N||Temperature responsive systems|
|US20060276844 *||May 18, 2006||Dec 7, 2006||Ruth Alon||Ingestible device for nitric oxide production in tissue|
|US20080188837 *||Dec 14, 2005||Aug 7, 2008||Ziv Belsky||Local Delivery of Drugs or Substances Using Electronic Permeability Increase|
|US20080215037 *||Apr 9, 2008||Sep 4, 2008||Petrakis Dennis N||Temperature responsive systems|
|US20080281273 *||Apr 29, 2008||Nov 13, 2008||Massachusetts Institute Of Technology||Microneedle transdermal transport device|
|US20080300535 *||Feb 20, 2008||Dec 4, 2008||Powderject Research Limited||Particle cassette, method and kit therefor|
|US20080319392 *||Jan 11, 2008||Dec 25, 2008||Angel Aimee B||Microneedle transport device|
|US20090041085 *||Sep 29, 2008||Feb 12, 2009||Petrakis Dennis N||Temperature responsive systems|
|US20090048555 *||Aug 11, 2008||Feb 19, 2009||Stryker Corporation||Drug delivery system|
|US20100286587 *||May 7, 2009||Nov 11, 2010||Yossi Gross||Sublingual electrical drug delivery|
|US20100286628 *||Jun 4, 2010||Nov 11, 2010||Rainbow Medical Ltd||Gastric anchor|
|US20100286660 *||May 7, 2009||Nov 11, 2010||Yossi Gross||Gastroretentive duodenal pill|
|US20110046479 *||Nov 1, 2010||Feb 24, 2011||Imran Mir A||System for marking a location for treatment within the gastrointestinal tract|
|US20110054354 *||Mar 3, 2011||Massachusetts Institute Of Technology||Nonlinear System Identification Techniques and Devices for Discovering Dynamic and Static Tissue Properties|
|US20110054355 *||Aug 31, 2010||Mar 3, 2011||Hunter Ian W||Identification Techniques and Device for Testing the Efficacy of Beauty Care Products and Cosmetics|
|US20110066175 *||Nov 5, 2010||Mar 17, 2011||Rainbow Medical Ltd.||Gastric anchor|
|US20130053928 *||May 31, 2012||Feb 28, 2013||Daniel Gat||Device, system and method for in vivo light therapy|
|DE3316934A1 *||May 9, 1983||Nov 10, 1983||Infusaid Corp||Implantierbares ventil|
|EP1398052A2 *||Dec 14, 2000||Mar 17, 2004||Phaeton Research Ltd||Ingestible device for the release of substances at distinct locations in the alimentary canal|
|EP1435920A1 *||Aug 30, 2002||Jul 14, 2004||Durect Corporation||Flow regulator|
|EP2816946A4 *||Jan 24, 2013||Nov 4, 2015||Capso Vision Inc||Power source control for medical capsules|
|WO1980001755A1 *||Feb 25, 1980||Sep 4, 1980||Andros Inc||Implantable infusion device|
|WO2001045789A3 *||Dec 14, 2000||Nov 8, 2001||Peter Hanson Hirst||Ingestible device for the release of substances at distinct locations in the alimentary canal|
|WO2004093942A2 *||Mar 17, 2004||Nov 4, 2004||Petrakis Dennis N||Temperature responsive systems|
|WO2004093942A3 *||Mar 17, 2004||Sep 9, 2005||Dennis N Petrakis||Temperature responsive systems|
|U.S. Classification||604/891.1, 604/288, 604/131, 604/249|
|May 8, 1986||AS02||Assignment of assignor's interest|
Owner name: CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUS
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, 300 LON
Effective date: 19860424
|May 8, 1986||AS||Assignment|
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, 300 LON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122
Effective date: 19860424
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, MASSACH